Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells
复制标题
程序性死亡1配体1和2在皮肤鳞状细胞癌中的表达及其与肿瘤浸润树突状细胞的关系
DOI：
10.1111/cei.12921
复制
发表时间：
2017-06-01
影响因子：
4.6
通讯作者：
Zhang, X.
中科院分区：
文献类型：
--
作者：
Jiao, Q.;Liu, C.;Zhang, X.
程序性死亡 1 (PD-1) 受体配体 PD-L1 和 PD-L2 是共刺激分子，有助于 T 淋巴细胞活化的负调节。目前尚不清楚PD-L1或PD-L2与皮肤鳞状细胞癌（CSCC）中的肿瘤浸润树突状细胞（TIDC）之间是否存在相关性。本研究旨在分析CSCC患者肿瘤组织中PD-L1和PD-L2的表达及树突状细胞浸润情况并探讨其临床意义。采用免疫组织化学分析方法评估 61 例 CSCC 组织中 PD-L1、PD-L2、CD1a 和 CD83 的表达情况。采用免疫荧光双标技术检测肿瘤组织中PD-L1或PD-L2与CD1a或CD83的共表达情况。我们发现，61 例 CSCC 中有 25 例 (40.98%) 表现出 PD-L1 阳性，而 61 例 CSCC 中有 37 例 (60.66%) 表现出 PD-L2 阳性。与CD83(-)阳性病例相比，PD-L1阳性和PD-L2阳性标本中CD1a阳性病例的比例较高（92.29% vs 37.60%、83.20% vs 33.16%）。 CSCC患者肿瘤组织中CD1a(+)细胞上PD-L1和PD-L2的表达显着高于CD83(+)细胞。此外，PD-L1的表达率与UICC分期相关，PD-L2的表达率与CSCC的主要分化和肿瘤大小相关。我们的结果表明，CSCC肿瘤组织中CD1a(+)细胞上PD-L1和PD-L2的表达高于CD83(+)细胞，可能有助于抗肿瘤免疫反应的负调节。
The programmed death-1 (PD-1) receptor ligands, PD-L1 and PD-L2, are co-stimulatory molecules that contribute to the negative regulation of T lymphocyte activation. It is still unclear whether there is correlation between PD-L1 or PD-L2 and tumour-infiltrating dendritic cells (TIDCs) in cutaneous squamous cell carcinoma (CSCC). The aim of this study was to analyse PD-L1 and PD-L2 expression and dendritic cells infiltration in tumour tissue of CSCC patients and investigate their clinical significance. Immunohistochemical analysis was used to evaluate the expression of PD-L1, PD-L2, CD1a and CD83 in 61 CSCC tissues. The immunofluoresence double-labelling technique was performed to detect the co-expression of PD-L1 or PD-L2 and CD1a or CD83 in tumour tissues. We found that 25 of 61 cases CSCC (40.98%) exhibited positivity for PD-L1, whereas 37 of 61 cases CSCC (60.66%) exhibited positivity for PD-L2. A higher percentage of CD1a-positive cases were observed on both PD-L1-positive and PD-L2-positive specimens compared with that of CD83(-) positive cases (92.29% versus 37.60%, 83.20% versus 33.16%). The expression of PD-L1 and PD-L2 on CD1a(+) cells was significantly higher than that on CD83(+) cells in tumour tissues of CSCC patients. Furthermore, the expression rate of PD-L1 was associated with UICC stage, and the expression rate of PD-L2 was associated with predominant differentiation and tumour size in CSCC. Our results indicated that higher expression of PD-L1 and PD-L2 on CD1a(+) cells than that on CD83(+) cells in CSCC tumour tissues may contribute to negative regulation in anti-tumour immune responses.